Detalhe da pesquisa
1.
Antisense oligonucleotides targeting the miR-29b binding site in the GRN mRNA increase progranulin translation.
J Biol Chem
; 299(12): 105475, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37981208
2.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Br J Dermatol
; 190(5): 668-679, 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226713
3.
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
J Am Acad Dermatol
; 90(4): 775-782, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38122848
4.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451052
5.
Deep learning for detection of iso-dense, obscure masses in mammographically dense breasts.
Eur Radiol
; 33(11): 8112-8121, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37209125
6.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36115523
7.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
J Am Acad Dermatol
; 88(1): 29-39, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35820547
8.
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
J Allergy Clin Immunol
; 149(6): 2010-2020.e8, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34767869
9.
Role of adropin in arterial stiffening associated with obesity and type 2 diabetes.
Am J Physiol Heart Circ Physiol
; 323(5): H879-H891, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36083795
10.
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Ann Rheum Dis
; 81(6): 815-822, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35241426
11.
Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction.
J Biol Chem
; 295(40): 13753-13768, 2020 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32727846
12.
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
N Engl J Med
; 379(14): 1313-1321, 2018 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30205746
13.
Artificial Intelligence-assisted chest X-ray assessment scheme for COVID-19.
Eur Radiol
; 31(8): 6039-6048, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33471219
14.
Supplementation With the Sialic Acid Precursor N-Acetyl-D-Mannosamine Breaks the Link Between Obesity and Hypertension.
Circulation
; 140(24): 2005-2018, 2019 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31597453
15.
Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis.
Rheumatol Int
; 40(7): 1021-1028, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32356115
16.
A review of virtual reality simulators for neuroendoscopy.
Neurosurg Rev
; 43(5): 1255-1272, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31444716
17.
Development of novel liverâ¯Xâ¯receptor modulators based on a 1,2,4-triazole scaffold.
Bioorg Med Chem Lett
; 29(3): 449-453, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30587446
18.
Correction: Deep learning for detection of iso-dense, obscure masses in mammographically dense breasts.
Eur Radiol
; 33(11): 8398, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37347431
19.
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.
Nature
; 485(7396): 62-8, 2012 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-22460951
20.
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
Ann Rheum Dis
; 76(9): 1550-1558, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28473423